These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15939713)

  • 1. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.
    Hutchings M; Mikhaeel NG; Fields PA; Nunan T; Timothy AR
    Ann Oncol; 2005 Jul; 16(7):1160-8. PubMed ID: 15939713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J; Qiao W; Wang C; Wang T; Xing Y
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Buhl T; Jurlander J; Buus S; Keiding S; D'Amore F; Boesen AM; Berthelsen AK; Specht L
    Blood; 2006 Jan; 107(1):52-9. PubMed ID: 16150944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.
    Mikhaeel NG; Hutchings M; Fields PA; O'Doherty MJ; Timothy AR
    Ann Oncol; 2005 Sep; 16(9):1514-23. PubMed ID: 15980161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
    Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
    Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
    Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012643. PubMed ID: 31930780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
    J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
    Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
    J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
    J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
    Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
    Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
    Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
    Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.